Aims: This trial aims to determine the effects of resistant starch (RS) subtype 2 (RS2) on glycemic status, metabolic endotoxemia and markers of oxidative stress. Methods: A randomized, controlled, parallel-group clinical trial group of 56 females with type 2 diabetes mellitus (T2DM) was divided to 2 groups. The intervention group (n = 28) and control group (n = 28) received 10 g/day RS2 or placebo for 8 weeks, respectively. Fasting blood samples were taken to determine glycemic status, endotoxin, high sensitivity C-reactive protein (hs-CRP), malondialdehyde (MDA), total antioxidant capacity (TAC), antioxidant enzymes concentrations as well as uric acid at baseline and after the intervention. Results: After 8 weeks, RS2 caused a significant decrease in the levels of MDA (-34.10%), glycosylated hemoglobin (-9.40%), insulin (-29.36%), homeostasis model of insulin resistance (-32.85%) and endotoxin (-25.00%), a significant increase in TAC (18.10%) and glutathione peroxidase (11.60%) as compared with control. No significant changes were observed in fasting plasma glucose, quantitative insulin sensitivity check index, hs-CRP, superoxide dismutase, catalase and uric acid in the RS2 group as compared with the control group. Conclusion: Supplementation with RS2 may be improved glycemic status, endotoxemia and markers of oxidative stress in patients with T2DM.

1.
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE: Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103:137-149.
2.
Lotfi MH, Saadati H, Afzali M: Prevalence of diabetes in people aged ≥ 30 years: the results of screen-ing program of Yazd province, Iran, in 2012. J Res Health Sci 2014;14:87-91.
3.
De Rosa S, Cirillo P, Paglia A, Sasso L, Di Palma V, Chiariello M: Reactive oxygen species and antioxidants in the pathophysiology of cardiovascular disease: does the actual knowledge justify a clinical approach? Curr Vasc Pharmacol 2010;8:259-275.
4.
Everard A, Cani PD: Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol 2013;27:73-83.
5.
Cui J, Le G, Yang R, Shi Y: Lipoic acid attenuates high fat diet-induced chronic oxidative stress and immunosuppression in mice jejunum: a microarray analysis. Cell Immunol 2009;260:44-50.
6.
Keshani P, Farvid M: Understanding the effective factors on high-fiber food consumption from the viewpoint of type 2 diabetic patients: a qualitative study (in Persian). Iran J Nutr Sci Food Technol 2012;7:11-22.
7.
Dehghan P, Gargari BP, Jafar-Abadi MA, Aliasgharzadeh A: Inulin controls inflammation and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized-controlled clinical trial. Int J Food Sci Nutr 2014;65:117-123.
8.
Dehghan P, Pourghassem Gargari B, Asghari Jafar-abadi M: Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial. Nutrition 2014;30:418-423.
9.
Homayouni A, Amini A, Keshtiban AK, Mortazavian AM, Esazadeh K, Pourmoradian S: Resistant starch in food industry: a changing outlook for consumer and producer. Starke 2014;66:102-114.
10.
Zhou Z, Cao X, Zhou JYH: Effect of resistant starch structure on short-chain fatty acids production by human gut microbiota fermentation in vitro. Starke 2013;65:509-516.
11.
Maki KC, Pelkman CL, Finocchiaro ET, Kelley KM, Lawless AL, Schild AL, et al: Resistant starch from high-amylose maize increases insulin sensitivity in overweight and obese men. J Nutr 2012;142:717-723.
12.
Kwak JH, Paik JK, Kim HI, Kim OY, Shin DY, Kim HJ, et al: Dietary treatment with rice containing resistant starch improves markers of endothelial function with reduction of postprandial blood glucose and oxidative stress in patients with prediabetes or newly diagnosed type 2 diabetes. Atherosclerosis 2012;224:457-464.
13.
Behall KM, Scholfield DJ, Hallfrisch JG, Liljeberg-Elmståhl HG: Consumption of both resistant starch and beta-glucan improves postprandial plasma glucose and insulin in women. Diabetes Care 2006;29:976-981.
14.
Bodinham CL, Smith L, Thomas EL, Bell JD, Swann JR, Costabile A, et al: Efficacy of increased resistant starch consumption in human type 2 diabetes. Endocr Connect 2014;3:75-84.
15.
Aigster A: Physicochemical and Sensory Properties of Resistant Starch-Based Cereal Products and Effects on Postprandial Glycemic and Oxidative Stress Responses in Hispanic Women. Virginia Polytechnic Institute and State University, 2009.
16.
Johnston KL, Thomas EL, Bell JD, Frost GS, Robertson MD: Resistant starch improves insulin sensitivity in metabolic syndrome. Diabet Med 2010;27:391-397.
17.
Pourghassem Gargari B, Dehghan P, Aliasgharzadeh A, Asghari Jafar-Abadi M: Effects of high performance inulin supplementation on glycemic control and antioxidant status in women with type 2 diabetes. Diabetes Metab J 2013;37:140-148.
18.
Del Rio D, Pellegrini N, Colombi B, Bianchi M, Serafini M, Torta F, et al: Rapid fluorimetric method to detect total plasma malondialdehyde with mild derivatization conditions. Clin Chem 2003;49:690-692.
19.
Aebi H: Catalase in vitro. Methods Enzymol 1984;105:121-126.
20.
Lobley GE, Holtrop G, Bremner DM, Calder AG, Milne E, Johnstone AM: Impact of short term consumption of diets high in either non-starch polysaccharides or resistant starch in comparison with moderate weight loss on indices of insulin sensitivity in subjects with metabolic syndrome. Nutrients 2013;5:2144-2172.
21.
Aliasgharzadeh A, Dehghan P, Pourghassem Gargari B, Asghari Jafarabadi M: Resistant dextrin, as a prebiotic, improves insulin resistance and inflammation in women with type 2 diabetes: a randomised controlled clinical trial. Br J Nutr 2015;113:321-330.
22.
Dehghan P, Pourghassem Gargari B, Asgharijafarabadi M: Effects of high performance inulin supplementation on glycemic status and lipid profile in women with type 2 diabetes: a randomized, placebo-controlled clinical trial. Health Promot Perspect 2013;3:55-63.
23.
Higgins JA, Higbee DR, Donahoo WT, Brown IL, Bell ML, Bessesen DH: Resistant starch consumption promotes lipid oxidation. Nutr Metab (Lond) 2004;1:8.
24.
Polakof S, Díaz-Rubio ME, Dardevet D, Martin JF, Pujos-Guillot E, Scalbert A, et al: Resistant starch intake partly restores metabolic and inflammatory alterations in the liver of high-fat-diet-fed rats. J Nutr Biochem 2013;24:1920-1930.
25.
Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, et al: Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2013;62:1112-1121.
26.
Kellow NJ, Coughlan MT, Savige GS, Reid CM: Effect of dietary prebiotic supplementation on advanced glycation, insulin resistance and inflammatory biomarkers in adults with pre-diabetes: a study protocol for a double-blind placebo-controlled randomised crossover clinical trial. BMC Endocr Disord 2014;14:55.
27.
Luo J, Van Yperselle M, Rizkalla SW, Rossi F, Bornet FR, Slama G: Chronic consumption of short-chain fructooligosaccharides does not affect basal hepatic glucose production or insulin resistance in type 2 diabetics. J Nutr 2000;130:1572-1577.
28.
Segain JP, Raingeard de la Blétière D, Bourreille A, Leray V, Gervois N, Rosales C, et al: Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000;47:397-403.
29.
Robert L, Narcy A, Rayssiguier Y, Mazur A, Rémésy C: Lipid metabolism and antioxidant status in sucrose vs. potato-fed rats. J Am Coll Nutr 2008;27:109-116.
30.
Prado-Silva L, Azevedo L, Oliveira JAC, Moreira APM, Schmiele M, Chang YK, et al: Sesame and resistant starch reduce the colon carcinogenesis and oxidative stress in 1,2-dimethylhydrazine-induced cancer in wistar rats. Food Res Int 2014;62:609-617.
31.
Scarminio V, Fruet AC, Witaicenis A, Rall VL, Di Stasi LC: Dietary intervention with green dwarf banana flour (Musa sp AAA) prevents intestinal inflammation in a trinitrobenzenesulfonic acid model of rat colitis. Nutr Res 2012;32:202-209.
32.
Gourineni VP, Verghese M, Boateng J, Shackelford L, Bhat KN: Chemopreventive potential of synergy1 and soybean in reducing azoxymethane-induced aberrant crypt foci in fisher 344 male rats. J Nutr Metab 2011;2011:983038.
33.
Russo I, Luciani A, De Cicco P, Troncone E, Ciacci C: Butyrate attenuates lipopolysaccharide-induced inflammation in intestinal cells and Crohn's mucosa through modulation of antioxidant defense machinery. PLoS One 2012;7:e32841.
34.
Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I: Melatonin suppresses markers of inflammation and oxidative damage in a human daytime endotoxemia model. J Crit Care 2014;29:184.e9-e13.
35.
Harazaki T, Inoue S, Imai C, Mochizuki K, Goda T: Resistant starch improves insulin resistance and reduces adipose tissue weight and CD11c expression in rat OLETF adipose tissues. Nutrition 2014;30:590-595.
36.
Morgantini C, Meriwether D, Baldi S, Venturi E, Pinnola S, Wagner AC, et al: HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease. Nutr Metab Cardiovasc Dis 2014;24:594-599.
37.
Johansson EV, Nilsson AC, Östman EM, Björck IM: Effects of indigestible carbohydrates in barley on glucose metabolism, appetite and voluntary food intake over 16 h in healthy adults. Nutr J 2013;12:46.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.